Adenoviral p53 gene therapy in head and neck squamous cell carcinoma cell lines

Yuzuru Higuchi, Jun Ichi Asaumi, Jun Murakami, Toru Wakasa, Tetsuyoshi Inoue, Masahiro Kuroda, Koichi Shibuya, Hiroshi Shigehara, Shoji Kawasaki, Kazuhiro Fukui, Kanji Kishi, Yoshio Hiraki

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We reconstructed the recombinant p53-expressing adenovirus and examined its infections and effects in head and neck squamous cell carcinoma cell lines. Eight human head and neck squamous cell carcinoma cell lines were infected by the recombinant adenovirus harboring the lacZ gene (AxCAiLacZ) or the wild-type p53 gene (AxCAip53), and the effects were investigated. The eight cell lines were successfully infected by AxCAiLacZ at a level of more than 50%. The survival of all 8 squamous cell lines were inhibited in the range from 8 to 26.7% by only one treatment of the AxCAip53 infection. This result suggested that p53 gene therapy might become a useful tool in head and neck squamous cell carcinoma treatment.

Original languageEnglish
Pages (from-to)1233-1236
Number of pages4
JournalOncology reports
Volume9
Issue number6
DOIs
Publication statusPublished - Nov 2002

Keywords

  • Adenovirus
  • Gene therapy
  • Squamous cell carcinoma
  • p53

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Adenoviral p53 gene therapy in head and neck squamous cell carcinoma cell lines'. Together they form a unique fingerprint.

  • Cite this

    Higuchi, Y., Asaumi, J. I., Murakami, J., Wakasa, T., Inoue, T., Kuroda, M., Shibuya, K., Shigehara, H., Kawasaki, S., Fukui, K., Kishi, K., & Hiraki, Y. (2002). Adenoviral p53 gene therapy in head and neck squamous cell carcinoma cell lines. Oncology reports, 9(6), 1233-1236. https://doi.org/10.3892/or.9.6.1233